Physician profile
Antonio Gregorian
NPI 1487740080
$9,272.14
in general payments reported to CMS, 2019-2025
41 companies · $3,097 in 2025
The $3,097 reported for 2025 was more than what 98% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,783 · 2020: $375 · 2021: $120 · 2022: $67.63 · 2023: $1,509 · 2024: $2,320 · 2025: $3,097.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,831 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,830.82 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,296.57 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $1,241.08 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $1,095.15 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $771.14 | 2019-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $547.27 | 2019-2025 | |
| Amgen INC. | $435.26 | 2019-2025 | Otezla, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $423.25 | 2019-2025 | Jardiance |
| Lilly USA, LLC | $387.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astellas Pharma US INC | $351.39 | 2019-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $306.11 | 2019-2025 | Gardasil 9, Capvaxive, Gardasil |
| Abbott Laboratories | $264.71 | 2019-2025 | Freestyle Libre 3 |
| Dexcom, INC. | $236.35 | 2024-2025 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $141.04 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $138.39 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $125.58 | 2023-2025 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Antonio Gregorian listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.